Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(HLA mismatch human leukocyte antigen mismatch)
1,154 results
  • Immunosuppression in sensitized recipients. [Journal Article]
    Curr Opin Organ Transplant 2020; 25(1):80-85Echterdiek F, Latus J, Schwenger V
  • CONCLUSIONS: Despite ever more challenging conditions, kidney transplantation in highly sensitized patients can be achieved with the use of dedicated programs, well established desensitizing agents and new drugs that specifically inhibit the molecular processes of AMR.
  • The Man with 2 Hearts: 25 Years from Heterotopic to Orthotopic Heart Transplantation. [Case Reports]
    Tex Heart Inst J 2019; 46(3):199-202Godfrey EL, Kueht ML, … Frazier OH
  • Substantial technological advances in mechanical circulatory support have caused a shift in the management of end-stage heart failure. From the 1970s through the 1990s, heterotopic heart transplantation was routinely performed in patients in whom orthotopic transplantation was likely to fail. Heterotopic heart transplantation is now performed less often because modern mechanical circulatory assis…
  • Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. [Journal Article]
    Lancet Haematol 2020; 7(1):e50-e60Petersdorf EW, Carrington M, … International Histocompatibility Working Group in Hematopoietic Cell Transplantation
  • CONCLUSIONS: The HLA-B leader informs GVHD risk after HLA-B-mismatched unrelated HCT and differentiates high-risk HLA-B mismatches from those with lower risk. The leader of the matched allotype could be considered to be as important as the leader of the mismatched allotype for GVHD. Prospective identification of leader-matched donors is feasible for most patients in need of a HCT, and could lower GVHD and increase availability of HCT therapy. These findings are being independently validated and warrant further research in prospective trials.
  • Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors. [Review]
    Cancers (Basel) 2019; 11(10)Oh S, Lee JH, … Choi SW
  • In treatments of solid tumors, adoptive transfer of ex vivo expanded natural killer (NK) cells has dawned as a new paradigm. Compared with cytotoxic T lymphocytes, NK cells take a unique position targeting tumor cells that evade the host immune surveillance by down-regulating self-antigen presentation. Recent findings highlighted that NK cells can even target cancer stem cells. The efficacy of al…
New Search Next